News - Novartis
WEBA legacy of blood cancer innovation. Media Release May 31, 2024. Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease. All news. Novartis in Society Integrated Report 2023.
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
WEB2 days ago · Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II …
Novartis Kisqali® shows deepening benefit in new analysis, …
WEB3 days ago · Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer. Sep 16, 2024. Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node ...
Novartis delivers double-digit sales growth and core margin …
WEBApr 23, 2024 · Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with substantial cash generation and a strong capital structure supporting continued flexibility.
Novartis unveils new focused strategy, underpinned by eight …
WEBSep 22, 2022 · Novartis is implementing this strategy with a clear focus on five therapeutic areas for investment - cardiovascular, immunology, neuroscience, solid tumors and hematology.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
WEB3 days ago · American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer success than originally thought.
Novartis announces new organizational structure to accelerate …
WEBBasel, April 4, 2022 — Novartis today announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.
FDA expands Novartis’ Kisqali label to include early breast cancer …
WEB1 day ago · The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients.
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
WEB19 hours ago · The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human...
Novartis Raises Outlook, Plans Buyback of Up to $15 Billion
WEBJul 18, 2023 · Novartis AG raised its profit outlook and announced plans to buy back as much as $15 billion in shares as it prepares to spin off its Sandoz generics unit.
Skip to content